Blocking cancer-specific mutations in leukemia and brain tumors

May 30, 2017, German Cancer Research Center
Candidate drug BAY1436032 (yellow) binds to the mutated enzyme IDH1. Credit: Stefan Pusch/DKFZ

The substitution of a single amino acid in a metabolic enzyme can be the cause of various types of cancer. Scientists from the German Cancer Research Center and Heidelberg University Hospital, collaborating with Bayer AG, have now been able to develop a candidate for an agent that is intended to specifically block the altered enzyme. First studies in mice have demonstrated preclinical effects of this investigational compound.

Many malignancies develop as a result of genetic alterations in individual . These gene mutations often cause altered proteins that give new, growth-promoting properties to the cell. A prime example for this principle is a -related altered form of the IDH1 enzyme that was initially discovered in certain .

Scientists had noticed that mutations in isocitrate dehydrogenase (IDH) 1 almost always occur at position 132 of the enzyme's chain of amino acids. This replacement causes a specific cancer-promoting metabolic product to accumulate in the cells. Non-mutated IDH enzymes in healthy cells do not produce this metabolite. "This prompted the idea of developing an agent that inhibits position 132-mutant IDH1," said Stefan Pusch from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). He added: "Our goal is to develop a drug that acts on while it does not influence with the normal enzyme."

In a research alliance with Bayer AG, the researchers from the DKFZ and Bayer jointly succeeded in finding a substance that is presumed to be highly selective. The investigational compound, called BAY1436032, is currently being examined in comprehensive preclinical tests for its safety and effectiveness.

Leukemia and brain cancer in mice slowed down

The 132 mutation of IDH1 has been found by now not only in various types of brain cancer (oligodendroglioma, diffuse astrocytoma and a smaller portion of glioblastomas) but also in approximately ten percent of acute myeloid leukemias (AML) as well as in bile duct cancer and certain malignant bone tumors. In two currently published studies, the Heidelberg researchers have now demonstrated the preclinical activity of BAY1436032 against AML and brain tumors (astrocytoma) in mice.

Under treatment with BAY1436032, mice that had been transplanted human astrocytoma cells survived significantly longer than untreated fellows. The agent, which can be administered with the food, substantially reduced the levels of the cancer-promoting metabolite in the cancer. "Even at high doses the animals tolerated the treatment well," said Andreas von Deimling, who is the head of a Clinical Cooperation Unit at the DKFZ and at Heidelberg University Hospital. "BAY1436032 really seems to act specifically on the mutated IDH1 in the cancer cells."

Tests of the agent against AML were also successful. Mice that had received IDH1-mutant human leukemia cells survived longer when treated with BAY1436032 than untreated animals did. Furthermore, the in their bone marrow were significantly reduced.

Cancer cells lose stem-cell properties

"There is evidence to suggest that BAY1436032 does not act cytotoxic, but may cause tumor cells to mature into normal blood cells instead," stated hemato-oncologist and scientist Alwin Krämer, who leads a Clinical Cooperation Unit of the German Cancer Research Center and Heidelberg University Hospital. Von Deimling, who led the preclinical study in gliomas, confirmed this observation: "The cancer cells in the mice under investigation lost their dangerous stem-cell characteristics and developed into precursors of normal brain cells".

As a couple of different mutations at amino acid position 132 of IDH1 are known, the research team also tested the effectiveness of the investigational compound against these mutational variants. In biochemical and cell culture assays, they could show that BAY1436032 is effective against all known mutational variants at position 132. In addition, there are indications that BAY1436032 may be able to cross the blood-brain barrier.

Following these promising preclinical results, a first clinical trial is currently being conducted at the Neurology Department of Heidelberg University Hospital. The trial comprises patients with glioma and other solid tumors with proven IDH1 mutation. The goal is to determine the tolerability of BAY1436032 and the appropriate dose. "Innovative therapies are greatly needed here," von Deimling said, "because therapy-resistant astrocytomas often turn into highly aggressive tumors that cannot be treated effectively with the drugs that are available at the present time."

In addition, an international clinical trial led by Alwin Krämer will shortly be launched to study the tolerability and the appropriate dose of BAY1436032 against IDH1 mutant AML.

Explore further: Experimental drugs that change energy supply in cells could slow brain tumor growth

More information: Stefan Pusch et al, Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo, Acta Neuropathologica (2017). DOI: 10.1007/s00401-017-1677-y

Related Stories

Experimental drugs that change energy supply in cells could slow brain tumor growth

December 14, 2015
Experimental drugs that alter cell metabolism also halted tumor growth and extended survival in mice with cancers linked to changes in the same gene, according to a new study led by researchers at NYU Langone Medical Center, ...

First positive results toward a therapeutic vaccine against brain cancer

June 25, 2014
Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. "Low-grade gliomas", which ...

Scientists identify key defect in brain tumor cells

February 1, 2017
In a new study, Yale researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA. They found that the defect is highly sensitive to an existing FDA-approved drug used to treat ...

TGen, Scottsdale Healthcare begin study of new drug for patients with solid tumors

June 17, 2014
The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, ...

Mutant-IDH1 inhibitor AG-120 shows early promise against solid tumors with IDH1 mutations

November 9, 2015
The investigational anticancer therapeutic AG-120, which targets mutant IDH1 protein, was well tolerated and showed signs of clinical activity in patients who had advanced solid tumors positive for mutant IDH1, according ...

Recommended for you

Largest-ever study of thyroid cancer genetics finds new mutations, suggests immunotherapy

April 26, 2018
University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid ...

Metastatic cancer gorges on fructose in the liver

April 26, 2018
Biomedical engineers at Duke University have demonstrated that metastatic cancer cells can reprogram their metabolism to thrive in new organs. Specifically, the research shows that cells originating from colorectal cancer ...

Molecular culprit behind virus-mediated chronic inflammation and cancers identified

April 26, 2018
Within cells infected by Kaposi sarcoma herpesvirus (KSHV), the human protein CADM1 interacts with viral proteins to promote chronic inflammation, which plays a major role in the development of cancers caused by KSHV. Richard ...

Blood cancer precursor found in 9/11 firefighters

April 26, 2018
A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

PARP-1 may be key to effectiveness of PARP inhibitors, and now researchers can image it

April 26, 2018
Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they've also proven they have a ...

Do prostate cancer cells have an Achilles' heel?

April 25, 2018
Researchers at the University of Illinois at Chicago describe new ways to selectively kill prostate cancer cells by exploiting the cells' revved-up metabolism. They report their findings in the online journal, eLife.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.